Currently, there are three types of immunotherapies currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma: (1) T-cell-stimulating cytokines (i.e., interferon (IFN)-α2b and interleukin-2 (IL-2)); (2) T-cell exhaustion-mitigating immune-checkpoint inhibitors (ICI); and (3) a dendritic cell (DC)-activating oncolytic virus (T-VEC). Here, IL2 is linked to melanoma.